Drug
Calcipotriene 0.005% Foam
Calcipotriene 0.005% Foam is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph early_phase_1
1
33%
Ph phase_1
2
67%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
completed267%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedearly_phase_1
Combination Topical Therapy for Treatment of Scalp Actinic Keratoses
NCT03996252
completedphase_1
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
NCT01582932
completedphase_1
Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis
NCT01563068
Clinical Trials (3)
Showing 3 of 3 trials
NCT03996252Early Phase 1
Combination Topical Therapy for Treatment of Scalp Actinic Keratoses
NCT01582932Phase 1
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
NCT01563068Phase 1
Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3